Tag: cancer profiling industry

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cancer Profiling Market Size Changed, over the years?

In recent years, the market size for cancer profiling has seen significant growth. It is projected to expand from $13.48 billion in 2024 to $15.05 billion in 2025, representing a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the past include an uptick in the rates of cancer diagnosis, an increase in the precision of medicine techniques, clinical usage of biomarkers, the development of drugs and targeted therapies as well as increased public awareness and advocacy for patients.

How Much Will the Cancer Profiling Market Be Worth in 2029?

The market size for cancer profiling is predicted to experience a swift expansion in the following years, reaching $23.08 billion in 2029, boasting a compound annual growth rate (CAGR) of 11.3%. The anticipated growth during the forecast period is linked to the inclusion of artificial intelligence, worldwide research partnerships, broadening the usage of liquid biopsy applications, regulatory backing for precision medicine, and a growing focus on early detection. The major market trends for the forecast period include the dominance of liquid biopsy, comprehensive genomic profiling, the rise of immunoprofiling, the growth of collaborative data sharing networks, and single-cell sequencing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which is the Largest Company in the Cancer Profiling Market?

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

What Are the Main Market Drivers in the Cancer Profiling Industry?

The rise in cancer prevalence is forecasted to boost the expansion of the cancer profiling market. The term “cancer incidence” refers to the number of new cancer diagnoses within a certain population over a specific duration. This surge in cancer cases can be attributed to urbanization, an increasing elderly population, lifestyle changes, as well as environmental and genetic aspects. Cancer profiling helps detect specific changes in a tumor’s molecular makeup, including gene mutations or changes in the tumor’s DNA, which greatly aids in the treatment process in cancer care. For example, in 2022, the American Cancer Society, a voluntary organization based in the U.S., predicted around 1.9 million new cancer diagnoses and approximately 609,360 cancer-related fatalities in the United States. Hence, this rising prevalence of cancer is fuelling the growth of the cancer profiling market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

How Is the Cancer Profiling Market Segments Structured?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Strategic Trends Are Transforming the Cancer Profiling Market?

Prominent companies in the cancer profiling industry are emphasizing innovation such as extensive coverage in their developments. This testing method examines 517 genes pertinent to cancer across almost 30 different types of solid tumors. Comprehensive or extensive coverage involves an all-inclusive examination of a variety of genetic mutations, biomarkers, or molecular targets. For instance, Illumina, Inc., a biotech company based in the US, debuted the TruSight Oncology Comprehensive (TSO) test in March 2022, marking a considerable progression in cancer diagnosis. This new diagnostic test for in vitro use in Europe identifies cancer mutations to guide patients towards specific therapies. It scans 517 genes across close to 30 types of solid tumors, analyzing both DNA and RNA. With a turnaround of four to five days, the test delivers results faster and complies with European quality standards marked by CE, meeting the demand for multiple gene tests on different tissue samples.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Global Regions Offer the Highest Growth in the Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

This Report Delivers Insight On:

1. How big is the cancer profiling market, and how is it changing globally?

2. Who are the major companies in the cancer profiling market, and how are they performing?

3. What are the key opportunities and risks in the cancer profiling market right now?

4. Which products or customer segments are growing the most in the cancer profiling market?

5. What factors are helping or slowing down the growth of the cancer profiling market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cancer profiling industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has the Cancer Profiling Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for cancer profiling has experienced swift expansion in the recent past. The forecasts predict an increase from $13.48 billion in 2024 to $15.05 billion in 2025, showing a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth during the historic period include the surge in cancer cases, adoption of precision medicine methods, clinical utilization of biomarkers, development of drugs and targeted treatments, enhanced awareness, and activism by patients.

In the coming years, the market size for cancer profiling is predicted to grow rapidly. By 2029, it is projected to reach $23.08 billion, moving at a compound annual growth rate (CAGR) of 11.3%. The anticipated expansion within this period can be traced back to factors such as the employment of artificial intelligence, research collaborations globally, expanded use of liquid biopsy, support from regulatory bodies for precision medicine, and an increased emphasis placed on early detection. Expect to see trends like dominance of liquid biopsy, extensive genomic profiling, the emergence of immunoprofiling, cooperative data sharing networks, and single-cell sequencing during this forecast period.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Cancer Profiling Market?

The upward trend in cancer occurrences is likely to fuel the expansion of the cancer profiling market in the future. Cancer incidence denotes the count of fresh cancer cases within a certain population over a given timeframe. This rising incidence is attributed to factors such as urbanization, an increasing elderly population, lifestyle transformations, as well as environmental and genetic influences. Cancer profiling is instrumental in pinpointing specific molecular or genetic alterations in a tumor, like gene mutations or other tumor DNA changes, which proves valuable in the course of cancer treatment. For example, as per the American Cancer Society—a US-based volunteer group—in 2022, the predicted count of new cancer diagnoses and death toll was around 1.9 million and 609,360 respectively, in the United States. Hence, the escalating rates of cancer is serving as a driving force for the growth of the cancer profiling market.

Which Key Market Segments Comprise the Cancer Profiling Market and Drive Its Revenue Growth?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Which Areas Are Leading Regions in the Cancer Profiling Market Expansion Across the Globe?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Key Market Trends in the Cancer Profiling Market Over the Coming Years?

Leading businesses in the cancer profiling market are making strides towards innovation with a focus on broad coverage. This type of testing investigates 517 genes that are significant to cancer in about 30 solid tumor types. Broad coverage involves a thorough review of a diverse assortment of genetic mutations, biomarkers, and molecular targets. For example, Illumina, Inc., a biotechnology firm based in the United States, introduced the TruSight Oncology Comprehensive (TSO) test in March 2022, which is a major breakthrough in cancer diagnosis. This new in vitro diagnostic test in Europe maps cancer mutations, directing patients towards targeted treatments. It scrutinizes 517 genes within almost 30 distinct types of solid tumors, examining both DNA and RNA. With results delivered within a span of four to five days, it accelerates the process and boasts a CE-mark for European quality standards, mitigating the need for multiple gene tests on various tissue specimens.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

How Is the Cancer Profiling Market Conceptually Defined?

Cancer profiling refers to a diagnostic procedure that is conducted to analyze the genetic information of tumor cells in the body. It provides information about certain molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Cancer Profiling Market?

The cancer profiling market is anticipated to expand due to the growing prevalence of cancer. The term “incidence of cancer” denotes the count of new cancer instances within a defined demographic during a set duration. The rising incidence of cancer can be attributed to urbanization, an expanding elderly populace, lifestyle modifications, and environmental and genetic influences. Cancer profiling facilitates the detection of specific molecular or genetic alterations in a tumor, like gene mutations or other changes in tumor DNA, which is instrumental to the cancer treatment process. For example, the American Cancer Society, a voluntary organization based in the U.S, projected in 2022 that there would be approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the U.S. Consequently, the escalating incidence of cancer is propelling the growth of the cancer profiling market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

#What Are the Key Projections for the CAGR of the Cancer Profiling Market From 2025 to 2034?

The market size for cancer profiling has significantly expanded in recent years. Projected growth indicates an increase from $13.48 billion in 2024 to $15.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this progression include an escalation in cancer diagnoses, the adoption of precision medicine methodologies, increased use of biomarkers in clinical settings, advances in drug development and targeted therapies, and a greater level of awareness and patient advocacy.

The market size for cancer profiling is set for a swift expansion in the forthcoming years, reaching a value of $23.08 billion in 2029 with a compound annual growth rate (CAGR) of 11.3%. Factors contributing to the expansion during the forecast period include the incorporation of artificial intelligence, worldwide research collaborations, widening use of liquid biopsy applications, regulatory backing for precision medicine, and a growing focus on early detection. Key trends in the forecast period comprise dominance of liquid biopsy, extensive genomic profiling, emergence of immunoprofiling, collaborative networks for data sharing, and single-cell sequencing.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

What Are the Key Market Innovations in theCancer Profiling Market Over the Coming Years?

Predominant businesses in the cancer profiling market are honing in on advancements such as broad coverage. This form of testing investigates 517 genes pertinent to cancer across approximately 30 different types of solid tumors. Broad coverage signifies the extensive analyzes conducted on a myriad of genetic mutations, molecular targets, or biomarkers. For example, in March 2022, the American biotechnology firm Illumina, Inc. introduced the TruSight Oncology Comprehensive (TSO) test, paving new pathways in cancer diagnostics. This novel in vitro diagnostic test in Europe evaluates cancerous mutations to steer patients towards specific therapies. It encompasses 517 genes spanning almost 30 solid tumor types, scrutinizing both DNA and RNA. With results available within four to five days, this expedited process is approved by the CE marking for quality standards in Europe, minimizing the necessity for multiple gene tests on diverse tissue samples.

Who Are the Top Companies Driving Innovation and Growth in theCancer Profiling Market?

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Which Key Market Segments Comprise the Cancer Profiling Market and Drive Its Revenue Growth?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smpGlobal Cancer Profiling Market, Global Cancer Profiling Market Report, Global Cancer Profiling Market Trends, Global Cancer Profiling Market Size

Browse Through More Reports Similar to the Gobal Cancer Profiling Maret 2025, By The Business Research Company:

Pain Management Devices And Therapies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Skin Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the cancer profiling market right now?

The market size for cancer profiling has expanded significantly in recent years. Its growth is projected to escalate from $13.48 billion in 2024 to approx $15.05 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. The historic period’s growth was primarily due to upticks in cancer incidence rates, the rise of precision medicine methods, broader clinical usage of biomarkers, advancements in drug development and targeted therapies, heightened awareness, and patient advocacy.

How fast Is the cancer profiling market expected to grow, and what’s its future value?

The size of the cancer profiling market is anticipated to experience swift progress in the forthcoming years. It is projected to augment to $23.08 billion by 2029, growing at a compounded annual growth rate (CAGR) of 11.3%. The amplified growth during the predicted period could be credited to factors such as the incorporation of artificial intelligence, global unified research efforts, the broadening realm of liquid biopsy applications, supportive regulatory measures for precision medicine, and a rising focus on early diagnosis. Influential trends during this future period are expected to encompass the predominance of liquid biopsy, inclusive genomic profiling, the emergence of immunoproofiling, cooperative data interchange platforms, and single-cell sequencing.

Get your cancer profiling market report here!

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

What are the leading drivers of growth in the cancer profiling market?

The surge in cancer cases is projected to boost the expansion of the cancer profiling market. The term ‘incidence of cancer’ means the count of fresh cancer diagnoses in a particular demographic over a stated time frame. This rise in cancer incidence is a result of urbanization, an aging population, lifestyle modifications, and environmental and genetic factors. Cancer profiling is beneficial in recognizing specific molecular or genetic alterations in a tumor, such as gene mutations or other DNA changes in the tumor, that can aid in the cancer treatment process. For example, in 2022, the American Cancer Society, a volunteer organization based in the U.S., projected that there would be an estimated 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the country. As a result, the escalating prevalence of cancer is fuelling the growth of the cancer profiling market.

What are the key segments defining the cancer profiling market?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Who are the key players steering the development of the cancer profiling market?

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

What emerging trends are influencing the growth of the cancer profiling market?

Leading businesses involved in the cancer profiling industry are concentrating on pioneering advancements, such as extensive coverage. This type of testing reviews 517 genes related to cancer across approximately 30 different solid tumor types. Extensive coverage implies an all-inclusive examination of various genetic mutations, biomarkers, or molecular targets. For example, Illumina, Inc., a biotechnology firm based in the US, debuted the TruSight Oncology Comprehensive (TSO) test in March 2022, signaling a substantial progression in cancer diagnostics. This newly launched in vitro diagnostic assessment in Europe profiles cancer mutations to direct patients towards specific therapies. It studies 517 genes in nearly 30 varieties of solid tumors, examining both DNA and RNA. With results available in just four to five days, it’s a quicker method and holds a CE mark for European quality standards, minimizing the necessity for multiple gene tests on diverse tissue samples.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

Which regions are most influential in expanding the cancer profiling market?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Pain Management Devices And Therapies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Skin Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Cancer Profiling Market: What’s the Expected CAGR for the Next Decade?

The market size for cancer profiling has seen significant growth in recent years. It is expected to surge from $13.48 billion in 2024 to $15.05 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth during the historic period include higher incidences of cancer, a rise in precision medicine approaches, clinical adoption of biomarkers, advancement in drug development and targeted therapies, along with increased awareness and patient advocacy.

In the upcoming years, a swift expansion is forecasted for the cancer profiling market, with projections suggesting a growth to $23.08 billion by 2029 through a compound annual growth rate (CAGR) of 11.3%. Factors contributing to this expansion during the forecast period include the incorporation of artificial intelligence, worldwide research collaborations, extension of liquid biopsy applications, regulatory endorsement for precision medicine, and a growing focus on early detection. Key trends that will define the forecast period encompass the dominance of liquid biopsy, comprehensive genomic profiling, the emergence of immunoprofiling, collaborative data-sharing networks, and single-cell sequencing.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the cancer profiling Market?

The rise in cancer occurrence is projected to stimulate the expansion of the cancer profiling market. The term “cancer incidence” denotes the tally of fresh cancer diagnoses within a specific demographic during a set duration. Factors such as urbanization, an aging population, lifestyle changes, and environmental and genetic contributors have accelerated cancer’s prevalence. Cancer profiling is essential in spotting particular molecular or genetic alterations in a tumor, like gene mutations or other changes in tumor DNA, playing a crucial role in the cancer treatment process. For example, in 2022, the American Cancer Society, a volunteer-based organization in the US, predicted around 1.9 million new cancer diagnosis and 609,360 cancer fatalities in the country. Consequently, the escalating occurrence of cancer is propelling the advancement of the cancer profiling market.

Request Your Free Cancer Profiling Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

What Are the Leading Organizations Impacting the Cancer Profiling Market’s Growth?

Major companies operating in the cancer profiling market include:

• Illumina Inc._x000D_

• Qiagen NV_x000D_

• NeoGenomics Inc._x000D_

• Sysmex Corporation_x000D_

• HTG Molecular Diagnostics Inc._x000D_

What Are the Most Prominent Trends Driving Change in the Cancer Profiling Market?

Prominent firms in the cancer profiling sector are striving to bring innovation to their operations, particularly in terms of exhaustive coverage. This refers to the extensive examination of various genetic aberrations, biomarkers, or molecular objectives. The test involves an assessment of 517 genes relevant to cancer and applicable to almost 30 different solid tumor forms. Illustratively, in March 2022, Illumina, Inc, a biotechnology corporation based in the US, rolled out its TruSight Oncology Comprehensive (TSO) test, a significant milestone in cancer detection. This innovative in vitro diagnostic procedure in Europe helps to profile cancer mutations, leading patients towards therapy specifically tailored for them. It spans 517 genes across close to 30 types of solid tumors, examining both DNA and RNA. The four- to five-day turnaround time ensures quicker results. Also, with a CE marking indicating compliance with European quality standards, the need for several gene assays on various tissue samples is considerably diminished.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

How Are Key Segments Defining the Competitive Landscape of the Cancer Profiling Market?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Regions Are Leading the Charge in the Cancer Profiling Market?

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Cancer Profiling Market Categorized and Defined in the Industry?

Cancer profiling refers to a diagnostic procedure that is conducted to analyze the genetic information of tumor cells in the body. It provides information about certain molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA.

Browse Through More Similar Reports By The Business Research Company:

Pain Management Devices And Therapies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Skin Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: